검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | erlotinib hydrochloride (erlotinib hydrochloride) Genentech, Inc.·Stage III Squamous Cell Carcinoma … ORR 39%·t½ 36.2 h |
|---|---|
Overview Program | erlotinib hydrochloride |
Overview Company | Genentech, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Stage III Squamous Cell Carcinoma of the |
Overview Indication | Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | Epidermal growth factor receptor (EGFR) is expressed on the cell surface of both normal and cancer cells |
MoA Biomarker | biomarkers in liver tissues |
PK/PD Half-life | 36.2 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Rat, Rabbit |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | Hepatotoxicity : Occurs with or without hepatic impairment, including hepatic failure and h |
Clinical Primary efficacy | ORR 39% |
Clinical ORR | 39% |
Clinical Result source | ClinicalTrials.gov NCT00280150 |
Clinical Data Tier / Score | A · 45 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | erlotinib hydrochloride (erlotinib hydrochloride) Genentech, Inc.·Stage III Squamous Cell Carcinoma … ORR 39%·t½ 36.2 h |
|---|---|
Overview Program | erlotinib hydrochloride |
Overview Company | Genentech, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Stage III Squamous Cell Carcinoma of the |
Overview Indication | Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | Epidermal growth factor receptor (EGFR) is expressed on the cell surface of both normal and cancer cells |
MoA Biomarker | biomarkers in liver tissues |
PK/PD Half-life | 36.2 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Rat, Rabbit |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | Hepatotoxicity : Occurs with or without hepatic impairment, including hepatic failure and h |
Clinical Primary efficacy | ORR 39% |
Clinical ORR | 39% |
Clinical Result source | ClinicalTrials.gov NCT00280150 |
Clinical Data Tier / Score | A · 45 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교